Literature DB >> 22956627

Loss of A(1) adenosine receptor attenuates alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice.

Ping Yang1, Peng Chen, Tao Wang, Yibei Zhan, Mengyi Zhou, Lin Xia, Rui Cheng, Yating Guo, Lin Zhu, Jianfa Zhang.   

Abstract

Cholestasis has limited therapeutic options and is associated with high morbidity and mortality. The A(1) adenosine receptor (A(1)AR) was postulated to participate in the pathogenesis of hepatic fibrosis induced by experimental extrahepatic cholestasis; however, the contribution of A(1)AR to intrahepatic cholestatic liver injury remains unknown. Here, we found that mice lacking A(1)AR were resistant to alpha-naphthyl isothiocyanate (ANIT)-induced liver injury, as evidenced by lower serum liver enzyme levels and reduced extent of histological necrosis. Bile acid accumulation in liver and serum was markedly diminished in A(1)AR(-/-) mice compared with wild-type (WT) mice. However, biliary and urinary outputs of bile acids were significantly enhanced in A(1)AR(-/-) mice. In the liver, mRNA expression of genes related to bile acid transport (Bsep and Mdr2) and hydroxylation (Cyp3a11) was increased in A(1)AR(-/-) mice. In the kidney, A(1)AR deficiency prevented the decrease of glomerular filtration rate caused by ANIT. Treatment of WT mice with A(1)AR antagonist DPCPX also protected against ANIT hepatotoxicity. Our results indicated that lack of A(1)AR gene protects mice from ANIT-induced cholestasis by enhancing toxic biliary constituents efflux through biliary excretory route and renal elimination system and suggested a potential role of A(1)AR as therapeutic target for the treatment of intrahepatic cholestasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956627     DOI: 10.1093/toxsci/kfs263

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

Review 1.  Purinergic signaling in hepatic disease.

Authors:  E Velázquez-Miranda; M Díaz-Muñoz; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2019-10-01       Impact factor: 3.765

2.  Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption.

Authors:  Haina Wang; Zhong-Ze Fang; Ran Meng; Yun-Feng Cao; Naoki Tanaka; Kristopher W Krausz; Frank J Gonzalez
Journal:  Toxicology       Date:  2017-05-24       Impact factor: 4.221

Review 3.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

Review 4.  I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis.

Authors:  Jordan J Feld; Élise G Lavoie; Michel Fausther; Jonathan A Dranoff
Journal:  F1000Res       Date:  2015-04-21

5.  Adenosine 5'-monophosphate ameliorates D-galactosamine/lipopolysaccharide-induced liver injury through an adenosine receptor-independent mechanism in mice.

Authors:  Y Zhan; Z Wang; P Yang; T Wang; L Xia; M Zhou; Y Wang; S Wang; Z Hua; J Zhang
Journal:  Cell Death Dis       Date:  2014-01-09       Impact factor: 8.469

6.  PER1 prevents excessive innate immune response during endotoxin-induced liver injury through regulation of macrophage recruitment in mice.

Authors:  T Wang; Z Wang; P Yang; L Xia; M Zhou; S Wang; Jie Du; J Zhang
Journal:  Cell Death Dis       Date:  2016-04-07       Impact factor: 8.469

Review 7.  Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity.

Authors:  Marta Vuerich; Rasika P Harshe; Simon C Robson; Maria Serena Longhi
Journal:  Int J Mol Sci       Date:  2019-01-27       Impact factor: 5.923

8.  Period1 mediates rhythmic metabolism of toxins by interacting with CYP2E1.

Authors:  Wenhao Ge; Tao Wang; Yang Zhao; Yunxia Yang; Qi Sun; Xiao Yang; Yan Gao; Xi Xu; Jianfa Zhang
Journal:  Cell Death Dis       Date:  2021-01-12       Impact factor: 8.469

9.  Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes.

Authors:  Lili Ding; Binfeng Zhang; Changsen Zhan; Li Yang; Zhengtao Wang
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.